Background:
- Approximately 5% of NSCLC occurs in patients 50 years or younger (median age:71) representing distinct clinicopathological features.
- Reports characterizing genomic alterations are scarce and limited by cost/availability of NGS.
- Using a large real-world (RW) dataset, we characterize oncogenic drivers, and immune landscapes to better understand YA with NSCLC.